Abstract
OBJECTIVE: To assess the performance of an adapted American Diabetes Association (ADA) risk score and the concise Finnish Diabetes Risk Score (FINRISC) for predicting type 2 diabetes development in women with and at risk of HIV infection. DESIGN: Longitudinal analysis of the Women's Interagency HIV Study. METHODS: The women's Interagency HIV Study is an ongoing prospective cohort study of women with and at risk for HIV infection. Women without prevalent diabetes and 3-year data on fasting blood glucose, hemoglobin A1c, self-reported diabetes medication use, and self-reported diabetes were included. ADA and FINRISC scores were computed at baseline and their ability to predict diabetes development within 3 years was assessed [sensitivity, specificity and area under the receiver operating characteristics (AUROC) curve]. RESULTS: A total of 1111 HIV-positive (median age 41, 60% African American) and 454 HIV-negative women (median age 38, 63% African-American) were included. ADA sensitivity did not differ between HIV-positive (77%) and HIV-negative women (81%), while specificity was better in HIV-negative women (42 vs. 49%, P = 0.006). Overall ADA discrimination was suboptimal in both HIV-positive [AUROC = 0.64 (95% CI: 0.58, 0.70)] and HIV-negative women [AUROC = 0.67 (95% CI: 0.57, 0.77)]. FINRISC sensitivity and specificity did not differ between HIV-positive (72 and 49%, respectively) and HIV-negative women (86 and 52%, respectively). Overall FINRISC discrimination was suboptimal in HIV-positive [AUROC = 0.68 (95% CI: 0.62, 0.75)] and HIV-negative women [AUROC = 0.78 (95% CI: 0.66, 0.90)]. CONCLUSION: Model performance was suboptimal in women with and at risk of HIV, while greater misclassification was generally observed among HIV-positive women. HIV-specific risk factors known to contribute to diabetes risk should be explored in these models.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2767-2775 |
| Number of pages | 9 |
| Journal | AIDS (London, England) |
| Volume | 32 |
| Issue number | 18 |
| DOIs | |
| State | Published - Nov 28 2018 |
Fingerprint
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases
Cite this
Predicting diabetes risk among HIV-positive and HIV-negative women. / Galaviz, Karla I.; Schneider, Michael F.; Tien, Phyllis C.; Mehta, C. Christina; Ofotokun, Ighovwerha; Colasanti, Jonathan; Marconi, Vincent C.; Palar, Kartika; Wingood, Gina; Adimora, Adaora A.; Alcaide, Maria; Cohen, Mardge H.; Gustafson, Deborah; Karim, Roksana; Konkle-Parker, Deborah; Merenstein, Daniel; Sharma, Anjali; Ali, Mohammed K.
In: AIDS (London, England), Vol. 32, No. 18, 28.11.2018, p. 2767-2775.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Predicting diabetes risk among HIV-positive and HIV-negative women
AU - Galaviz, Karla I.
AU - Schneider, Michael F.
AU - Tien, Phyllis C.
AU - Mehta, C. Christina
AU - Ofotokun, Ighovwerha
AU - Colasanti, Jonathan
AU - Marconi, Vincent C.
AU - Palar, Kartika
AU - Wingood, Gina
AU - Adimora, Adaora A.
AU - Alcaide, Maria
AU - Cohen, Mardge H.
AU - Gustafson, Deborah
AU - Karim, Roksana
AU - Konkle-Parker, Deborah
AU - Merenstein, Daniel
AU - Sharma, Anjali
AU - Ali, Mohammed K.
PY - 2018/11/28
Y1 - 2018/11/28
N2 - OBJECTIVE: To assess the performance of an adapted American Diabetes Association (ADA) risk score and the concise Finnish Diabetes Risk Score (FINRISC) for predicting type 2 diabetes development in women with and at risk of HIV infection. DESIGN: Longitudinal analysis of the Women's Interagency HIV Study. METHODS: The women's Interagency HIV Study is an ongoing prospective cohort study of women with and at risk for HIV infection. Women without prevalent diabetes and 3-year data on fasting blood glucose, hemoglobin A1c, self-reported diabetes medication use, and self-reported diabetes were included. ADA and FINRISC scores were computed at baseline and their ability to predict diabetes development within 3 years was assessed [sensitivity, specificity and area under the receiver operating characteristics (AUROC) curve]. RESULTS: A total of 1111 HIV-positive (median age 41, 60% African American) and 454 HIV-negative women (median age 38, 63% African-American) were included. ADA sensitivity did not differ between HIV-positive (77%) and HIV-negative women (81%), while specificity was better in HIV-negative women (42 vs. 49%, P = 0.006). Overall ADA discrimination was suboptimal in both HIV-positive [AUROC = 0.64 (95% CI: 0.58, 0.70)] and HIV-negative women [AUROC = 0.67 (95% CI: 0.57, 0.77)]. FINRISC sensitivity and specificity did not differ between HIV-positive (72 and 49%, respectively) and HIV-negative women (86 and 52%, respectively). Overall FINRISC discrimination was suboptimal in HIV-positive [AUROC = 0.68 (95% CI: 0.62, 0.75)] and HIV-negative women [AUROC = 0.78 (95% CI: 0.66, 0.90)]. CONCLUSION: Model performance was suboptimal in women with and at risk of HIV, while greater misclassification was generally observed among HIV-positive women. HIV-specific risk factors known to contribute to diabetes risk should be explored in these models.
AB - OBJECTIVE: To assess the performance of an adapted American Diabetes Association (ADA) risk score and the concise Finnish Diabetes Risk Score (FINRISC) for predicting type 2 diabetes development in women with and at risk of HIV infection. DESIGN: Longitudinal analysis of the Women's Interagency HIV Study. METHODS: The women's Interagency HIV Study is an ongoing prospective cohort study of women with and at risk for HIV infection. Women without prevalent diabetes and 3-year data on fasting blood glucose, hemoglobin A1c, self-reported diabetes medication use, and self-reported diabetes were included. ADA and FINRISC scores were computed at baseline and their ability to predict diabetes development within 3 years was assessed [sensitivity, specificity and area under the receiver operating characteristics (AUROC) curve]. RESULTS: A total of 1111 HIV-positive (median age 41, 60% African American) and 454 HIV-negative women (median age 38, 63% African-American) were included. ADA sensitivity did not differ between HIV-positive (77%) and HIV-negative women (81%), while specificity was better in HIV-negative women (42 vs. 49%, P = 0.006). Overall ADA discrimination was suboptimal in both HIV-positive [AUROC = 0.64 (95% CI: 0.58, 0.70)] and HIV-negative women [AUROC = 0.67 (95% CI: 0.57, 0.77)]. FINRISC sensitivity and specificity did not differ between HIV-positive (72 and 49%, respectively) and HIV-negative women (86 and 52%, respectively). Overall FINRISC discrimination was suboptimal in HIV-positive [AUROC = 0.68 (95% CI: 0.62, 0.75)] and HIV-negative women [AUROC = 0.78 (95% CI: 0.66, 0.90)]. CONCLUSION: Model performance was suboptimal in women with and at risk of HIV, while greater misclassification was generally observed among HIV-positive women. HIV-specific risk factors known to contribute to diabetes risk should be explored in these models.
UR - http://www.scopus.com/inward/record.url?scp=85056412087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056412087&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000002017
DO - 10.1097/QAD.0000000000002017
M3 - Article
C2 - 30289812
AN - SCOPUS:85056412087
VL - 32
SP - 2767
EP - 2775
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 18
ER -